TYRATyra Biosciences, Inc.vs its industry peers
A metric-by-metric comparison of Tyra Biosciences, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Empresa | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TYRAEsta | $1.2B#4 | — | 3.5x#6 | — | — | -38.7%#3 | — | -33.9%#5 | — | — | 31.6%#2 | — |
| DMRA | $1.3B#1 | 2.7x#1 | 2.5x#4 | — | — | -878.8%#6 | — | -40.7%#6 | — | — | 183.2%#1 | — |
| NKTR | $1.3B#2 | — | 1.4x#3 | 23.3x#3 | -43.9%#4 | -37.8%#2 | -253.7%#3 | -18.2%#3 | -14.0%#3 | — | -42.0%#5 | — |
| OPK | $1.3B#3 | — | 1.1x#1 | 2.1x#1 | -14.9%#3 | -324.0%#5 | -19.3%#2 | -19058.1%#7 | -13.3%#2 | 4#2 | 25.5%#3 | — |
| JANX | $1.1B#5 | — | 1.2x#2 | 107.8x#4 | -5.6%#2 | -64.7%#4 | -1576.7%#4 | -12.2%#2 | — | — | — | — |
| SPTX | $1.1B#6 | — | 2.6x#5 | — | — | — | — | 0.0%#1 | — | — | — | — |
| HROW | $1.0B#7 | — | 69.0x#7 | 3.9x#2 | 36.4%#1 | 70.6%#1 | 11.2%#1 | -33.8%#4 | 13.2%#1 | 6#1 | -25.9%#4 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. Esta tabla agotó el tiempo durante su construcción, por lo que cubre parte del grupo; los rangos son solo dentro de las filas mostradas y se completará en breve. Table built 2026-11-03.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice